Isomorphic Labs Raises $5 Billion Series C, Largest Life-Sciences VC Round Ever

  • Dispatched: Nov 18, 2026 · 18:18 ET (23:18 UTC)

One-sentence summary: Isomorphic Labs, the Alphabet-owned AI drug-discovery company spun out of Google DeepMind, announced on 2026-11-17 07:00 ET / 12:00 UTC a $5 billion Series C co-led by Greenoaks and Sequoia Capital, which the UK BioIndustry Association called the largest venture capital raise in life sciences ever.

Verification status: ✓ Official first-party disclosure (Isomorphic Labs company news release); reported the same day by TechCrunch.

Core Facts & Consensus Delta:

  • Financing: $5 billion Series C, announced 2026-11-17 07:00 ET / 12:00 UTC. Co-led by Greenoaks and Sequoia Capital; new investors include Andreessen Horowitz, with continued significant investment from Alphabet and participation from all existing investors (Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund).
  • Pace: Six months after a $2.1 billion Series B announced on 2026-05-12; the two rounds total $7.1 billion, taking cumulative funding above $7.7 billion.
  • Valuation: The company did not disclose a valuation for the round; Bloomberg had earlier reported it sought funding at about a $50 billion valuation, not yet confirmed.
  • Use of proceeds: Scaling its proprietary drug-design engine IsoDDE, its internal and partnered pipeline, and global bioengineering infrastructure, to move AI-designed oncology and immunology candidates into the clinic; the company expects to file its first Investigational New Drug application and begin first-in-human testing before the end of 2026.
  • Company background: Spun out of Google DeepMind in 2021; CEO Demis Hassabis, 2024 Nobel laureate in Chemistry for AlphaFold. No candidate has yet entered human trials; all programmes remain preclinical.

Supply-Chain & Market Read-Through:

  • AI drug-discovery commercialisation: As the flagship AI-pharma asset in the DeepMind ecosystem, a $5 billion raise sets a funding benchmark for taking AI-designed medicines from computational validation into the clinic; milestone payments and pipeline progress with partners Eli Lilly, Novartis and Johnson & Johnson stand to benefit directly.
  • Capital markets: In the same week Anthropic priced its IPO at $83 a share ahead of a 2026-11-19 debut, two large AI-related financings landed together — a sign that primary-market funding for leading AI assets is still expanding, not contracting.
  • Compute side: Scaling IsoDDE's simulation models and agents will add demand for high-performance computing and AI infrastructure, though the volume remains modest next to hyperscaler capital expenditure.

Next Catalysts & Watchpoints:

  • Before the end of 2026: The first Investigational New Drug filing and first-in-human dosing, testing whether AI-designed molecules can reach the clinic.
  • Any later disclosure of the round's valuation, and milestone progress in the Lilly, Novartis and Johnson & Johnson collaborations.

Sources:

Information only, not investment advice.

→ 阅读中文版

More flash alerts from 2026-11-18

INSTANT ARCHIVE SEARCH

Search Stocks, Earnings & Macro Alerts

Quick tags: